Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017.

Ann Oncol 28 (Supplement 5)(958P), 341. doi:10.1093/annonc/mdx372